ReviewJournal of neurology2023
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
Review in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions.Frontiers in neurology · 2025Pooled it
- Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkers.Frontiers in neurology · 2025Pooled it
- Clinical and radiological characteristics of MOG antibody-associated disease (MOGAD): a comparative study between pediatric and adult cohorts.Acta neurologica Belgica · 2026Article
- Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.Cell death and differentiation · 2026Review
- A practical alternative to live cell-based assay for AQP4 and MOG antibody detection.EBioMedicine · 2026Article
- Cerebellar Involvement in Immune-Mediated Pediatric Acute Ataxia: Clinical Spectrum, MRI Findings, and Predictors of MOG Antibody Positivity.Cerebellum (London, England) · 2026Article
- Myelin oligodendrocyte glycoprotein antibody-associated disease after transforaminal lumbar interbody fusion surgery: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children.Annals of clinical and translational neurology · 2026Article
- MOGAD update: new phenotypes in the expanding clinical spectrum.Journal of neurology · 2026Review
- Successful treatment with efgartigimod as rescue therapy in acute attack of MOGAD: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Functional and structural outcomes in paediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a prospective study.Documenta ophthalmologica. Advances in ophthalmology · 2026Article
- CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.Journal of neuroinflammation · 2026Review
- Acute Disseminated Encephalomyelitis (ADEM): Current View into Etiopathogenesis and Clinical Features.Brain sciences · 2026Review
- Live-Cell-Based Assay Outperforms Fixed Assay in MOGAD Diagnosis: A Retrospective Validation Against the 2023 International Criteria.Diagnostics (Basel, Switzerland) · 2026Article
- Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future.Frontiers in immunology · 2026Review
- Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.Therapeutic advances in neurological disorders · 2026Article
- MOG-Ab-associated optic neuritis with concurrent GFAP-Ab positivity following tislelizumab-based treatment: a case report.Frontiers in pharmacology · 2026Article
- Isolated Sixth Cranial Nerve Palsy as the First Presenting Sign of MOG Antibody-Associated Disease in a Three-Year-Old Child.The British and Irish orthoptic journal · 2026Article
- Retrospective analysis of the clinical features of 12 cases of MOG antibody-associated aseptic meningitis.Frontiers in medicine · 2026Article
- Longitudinal Brain Atrophy Patterns in Early MOG-Antibody Associated Disease and Relapsing Multiple Sclerosis.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) have recently been proposed, distinguishing this syndrome from other inflammatory diseases of the central nervous system. Seropositivity status for MOG-IgG autoantibodies is important for diagnosing MOGAD, but only in the context of robust clinical characterization and cautious interpretation of neuroimaging. Over the last several years, access to cell-based assay (CBA) techniques has improved diagnostic accuracy, yet the positive predictive value of serum MOG-IgG values varies with the prevalence of MOGAD in any given patient population. For this reason, possible alternative diagnoses need to be considered, and low MOG-IgG titers need to be carefully weighted. In this review, cardinal clinical features of MOGAD are discussed. Key challenges to the current understanding of MOGAD are also highlighted, including uncertainty regarding the specificity and pathogenicity of MOG autoantibodies, the need to identify immunopathologic targets for future therapies, the quest to validate biomarkers that facilitate diagnosis and detect disease activity, and the importance of deciphering which patients with MOGAD require long-term immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.